Sarlósejtes vérszegénység: vizsgálatok itt: Törökország
9 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Where
- Adana, Ankara, Mezitli, Yenişehir
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07224360 · EU 2025-521154-42-00 - 4. fázisCsak meghívásosA Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
- Where
- Seyhan
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00 - 1/2. fázisTaking peopleA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- Where
- Adana, Ankara
- Életkor
- 12 év to 55 év
- People
- 161 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06546670 · EU 2024-515696-35-00 - 3. fázisTaking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- Adana, Mersin
- Életkor
- 10 év to 65 év
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - 2. fázisTaking peopleSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Where
- Adana, Ankara, Istanbul, Mezitli-Mersin, Seyhan, Seyhan/Adana, Yenişehir
- Életkor
- 12 év and over
- People
- 70 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06699849 · EU 2024-513440-29-00 - 2. fázisBefejeződöttA Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- Where
- Ankara, Seyhan
- Életkor
- 6 hónap to 18 év
- People
- 95 worldwide
- Run by
- Forma Therapeutics, Inc.
See details and how to joinNCT06198712 · EU 2024-519881-32-00 - 3. fázisTaking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- Adana, Ankara, Mersin
- Életkor
- 2 év and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - 3. fázisTaking peopleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Adana, Ankara, Mersin
- Életkor
- 12 év and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - 4. fázisFut, nem toborozRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- Where
- Adana, Hatay
- Életkor
- 6 hónap to 100 év
- People
- 130 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00